Ociperlimab is a humanized IgG1 monoclonal antibody targeting the T cell immunoreceptor with Ig and ITIM domains (TIGIT). It exhibits high-affinity binding to the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. By inhibiting the interaction between TIGIT and its ligands, poliovirus receptor (PVR) and PVR-like 2 (PVR-L2), Ociperlimab serves as a potent tool in the modulation of immune responses. This antibody is particularly useful in the research of cancer immunotherapy, facilitating the study of TIGIT as an immune checkpoint in various oncological models.
Ociperlimab is a humanized IgG1 monoclonal antibody targeting the T cell immunoreceptor with Ig and ITIM domains (TIGIT). It exhibits high-affinity binding to the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. By inhibiting the interaction between TIGIT and its ligands, poliovirus receptor (PVR) and PVR-like 2 (PVR-L2), Ociperlimab serves as a potent tool in the modulation of immune responses. This antibody is particularly useful in the research of cancer immunotherapy, facilitating the study of TIGIT as an immune checkpoint in various oncological models.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
